<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-22T14:39:06Z</responseDate><request verb="GetRecord" identifier="oai:digital.lib.washington.edu:1773/49720" metadataPrefix="dim">https://digital.lib.washington.edu/server/oai/request</request><GetRecord><record><header><identifier>oai:digital.lib.washington.edu:1773/49720</identifier><datestamp>2026-02-15T21:16:18Z</datestamp><setSpec>com_1773_4888</setSpec><setSpec>col_1773_4941</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Atkins, William M</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author" authority="58e72d42-fbe9-4082-85e8-ecb808e3e5f9" confidence="300">Larsen, Hayli Alissa</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2023-01-21T05:04:41Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2023-01-21</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="submitted">2022</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other">Larsen_washington_0250E_25036.pdf</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/1773/49720</dim:field>
   <dim:field mdschema="dc" element="description">Thesis (Ph.D.)--University of Washington, 2022</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract">Antibody-based therapeutics are some of the best-selling drugs on the market with indications in several aggressive cancers, chronic autoimmune conditions, and other disease states. 
They provide several advantages over traditional small molecule drugs but factors controlling the
pharmacokinetics (PK) and pharmacodynamics (PD) are less understood. A key contributing 
factor is a lack of understanding of how proteins are affected by complex, crowded biological 
environments such as serum and plasma. This is largely because techniques used in the 
biopharmaceutical industry are poorly suited for neat ex vivo samples. For this reason, the complex 
effects of crowding in the therapeutic context of efficacy and clearance have not been documented. 
The second virial coefficient (B2) parameter quantifies such weak interactions and can be 
determined by a variety of techniques; however, probing nonideality in complex biological fluids 
remains challenging. 
Fluorescence correlation spectroscopy (FCS) is a technique capable of measuring the 
diffusive properties of proteins directly in biological fluids. Therefore, the focus of this dissertation 
is to utilize FCS to explore nonideality and antibody-target interactions directly in undilute serum. 
Chapter 1 introduces important topics related to antibody structure and function, therapeutic 
antibody optimization, and macromolecular crowding. Chapter 2 presents the development and 
validation of a novel in-serum FCS approach for probing nonideality via determination of apparent 
second virial coefficients (B2,app). The findings revealed that nonideality effects in serum are 
antibody dependent. In Chapter 3, the in-serum FCS approach is utilized to further characterize 
the origins of nonideality. Here, B2,app measurements were used to identify the components of 
human serum responsible for non-ideal interactions with mAbs and Fab fragments. Most notably, 
attractive interactions were observed with serum IgGs in Fab domains. Therefore, Chapter 4 
utilizes FCS to investigate the impact of nonideality on antigen binding. As a preliminary 
assessment, a model system was used to determine antibody-antigen affinity in buffer and serum 
via FCS. In addition, correlations between B2,app and serum-induced changes in binding affinity 
were explored. This provided initial insight into the significance of the magnitude of B2,app values, 
where slight attraction in the model system did not result in functional consequences to antigen 
binding. Together, this work demonstrates the potential utility of FCS in the biopharmaceutical 
industry and provides the foundation for investigating the impact of nonideality on the biophysical 
properties of therapeutic antibodies in physiological environments.</dim:field>
   <dim:field mdschema="dc" element="format" qualifier="mimetype">application/pdf</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso">en_US</dim:field>
   <dim:field mdschema="dc" element="rights">none</dim:field>
   <dim:field mdschema="dc" element="subject">macromolecular crowding</dim:field>
   <dim:field mdschema="dc" element="subject">nonideality</dim:field>
   <dim:field mdschema="dc" element="subject">therapeutic antibodies</dim:field>
   <dim:field mdschema="dc" element="subject">Pharmaceutical sciences</dim:field>
   <dim:field mdschema="dc" element="subject" qualifier="other">Medicinal chemistry</dim:field>
   <dim:field mdschema="dc" element="title">The Impact of Nonideality on the Biophysical Properties of Therapeutic Antibodies in Physiological Environments</dim:field>
   <dim:field mdschema="dc" element="type">Thesis</dim:field>
   <dim:field mdschema="dc" element="embargo" qualifier="terms">Restrict to UW for 2 years -- then make Open Access</dim:field>
   <dim:field mdschema="dc" element="embargo" qualifier="lift">2025-01-10T05:04:41Z</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim>
</metadata></record></GetRecord></OAI-PMH>